Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.
about
Vaccinia recombinant virus expressing the rabies virus glycoprotein: safety and efficacy trials in Canadian wildlife.Poxvirus pathogenesisMetastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2Combined prime-boost vaccination against tick-borne encephalitis (TBE) using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non-structural NS1 proteinUse of Reporter Genes in the Generation of Vaccinia Virus-Derived VectorsReplication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical DataNovel approaches to develop Rift Valley fever vaccinesRecombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challengeOncolytic virotherapy for pediatric malignancies: future prospectsHuman poxvirus infection after the eradication of smallpoxInduction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes.Effects of virally expressed interleukin-10 on vaccinia virus infection in mice.Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccinesAntiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals.Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates.Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.Infection control in gene therapy.Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus.Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicityHighly attenuated vaccinia virus mutants for the generation of safe recombinant virusesYaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy.Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen.Camelpox virus encodes a schlafen-like protein that affects orthopoxvirus virulence.Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesHuman respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challengeSteroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factorImmune response in skunks to a vaccinia virus recombinant expressing the rabies virus glycoprotein.Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteinsVaccinia virus vectors: new strategies for producing recombinant vaccines.Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccineCurrent approaches to vaccine preparation.Immunodomination during peripheral vaccinia virus infection.Host factor SAMHD1 restricts DNA viruses in non-dividing myeloid cellsDeletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion.Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in miceA mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanomaFuture directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus.
P2860
Q24535640-46B7F587-09B7-4E49-949C-F40A96D68A26Q24634729-FFB4DABD-22B1-42FE-9781-F951929B93B4Q24792515-887EDFC9-4E2A-4133-B1B7-8D70ADD4DD10Q24813809-C26AF9D1-6CB4-4941-A4D1-F0CD2DAC3721Q26746915-FD6AAB7E-9BDB-46C8-85B9-2F68EBD99D85Q26801501-652B6954-A7C6-4992-BE02-C0622CE69D3EQ27027003-A5E91785-78AB-45A4-AE3E-F2C7A28DC7EBQ27486835-48A5A3A6-9042-45B1-A9EC-F42AA7B84696Q28069358-D3443A16-148E-4786-A5FA-206D41181E64Q28767649-BBEBAC0B-269A-4D07-9F89-EE28A96ECA9AQ30339052-415A94D6-3A9F-4DF6-86A6-3F589E6B3DFCQ30452141-2CDC6705-FAE9-4450-8E14-0E6E18C6980BQ33210436-E772ABB7-6567-4C72-8460-BEA47A4FDBFDQ33558337-19D5EFCA-3E02-4AED-97C4-6DEDBA04F194Q33558384-91E420EA-5C4D-44B1-84FF-B31A5A9202C5Q33587040-2163269F-9B37-4FFF-968B-1B20BEBED0FAQ33625843-36270827-4B02-4677-96C7-872B95FE4842Q33722265-14AD6728-564A-495B-98DB-823B6570D190Q33792968-5BE133EE-57C5-403F-9F97-402D319E8622Q33834391-5E7B143F-65E9-4501-A79E-2F55119E81D9Q33838030-76C8DA83-16C0-43B4-BEDE-D7F7663DDFD4Q33847896-235A7893-24C9-49D8-9DBE-C586DD7F553CQ33855119-3C29C751-7AC1-4AF1-B9A6-7C8361B534FFQ33913025-E0A8B42B-270A-40FF-B7CD-1F3FBA8D65D9Q33924550-BA27AB39-6E8B-46A6-8705-386686FD27B7Q33928414-A1C28E91-ABEE-49AA-B1A3-534C01D01756Q33937787-12E631D0-D5DD-4F18-ABE6-074CAA86C82DQ34080569-870DD70C-1233-46BC-9709-75293DCC1E17Q34106038-4AB6A076-74A2-433E-82AE-41D25CCE9E83Q34211635-14E16572-ED4F-4653-A078-364F204C9374Q34212910-044AE858-FA1A-4379-B03B-3DAE833DD708Q34431934-5E66ECEF-CEA3-4ABC-A45E-60FC1C136C22Q34688016-225DCF76-F17D-4054-A018-BEDCFA4F8AB1Q34697921-459B412C-A7A5-4AF5-98E4-1449E51C6B8AQ34795512-EC398F92-CCF7-4E00-B32A-EA2FF2B7B85EQ35076706-0A4979F4-E3C6-4815-828E-70099C105748Q35113336-55B46278-7D8A-47A2-9DE1-C6FCE54201DAQ35202797-0EE24090-B7E8-4E67-A4D4-AD2D05AF9E16Q35285695-9B10D00D-FE27-4529-ACB2-D0FDA9D54334Q35842621-93DDC8EE-5D1A-41DD-B88B-F71D431F36E4
P2860
Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh-hant
name
Decreased virulence of recombi ...... ine kinase-negative phenotype.
@en
Decreased virulence of recombi ...... ine kinase-negative phenotype.
@nl
type
label
Decreased virulence of recombi ...... ine kinase-negative phenotype.
@en
Decreased virulence of recombi ...... ine kinase-negative phenotype.
@nl
prefLabel
Decreased virulence of recombi ...... ine kinase-negative phenotype.
@en
Decreased virulence of recombi ...... ine kinase-negative phenotype.
@nl
P2093
P356
P1433
P1476
Decreased virulence of recombi ...... ine kinase-negative phenotype.
@en
P2093
P2888
P304
P356
10.1038/317813A0
P407
P577
1985-10-01T00:00:00Z
P6179
1005453719